Prapela

Executive Summary

Prapela is a Boston-based medical device company addressing critical unmet needs in neonatal care. Its flagship product is a vibrating bassinet pad designed to reduce suffering in opioid-exposed newborns (Neonatal Opioid Withdrawal Syndrome, NOWS). The device has received FDA marketing authorization, making it the first and only treatment of its kind for NOWS. Additionally, Prapela is conducting a clinical trial to evaluate the pad's effectiveness in reducing apnea and improving breathing and oxygenation in preterm infants. The company operates at the intersection of the opioid crisis and preterm birth complications, two major challenges in neonatology. With a founding date of 2019, Prapela has positioned itself as an early mover in non-pharmacological neonatal stimulation therapy. The potential market is significant, given the ongoing opioid epidemic and the high incidence of apnea in premature infants.

Upcoming Catalysts (preview)

• Q3 2026Publication of clinical trial results for preterm apnea reduction60% success
• TBDFDA expansion of indications for broader neonatal respiratory support50% success
• TBDCommercial partnership or licensing deal for NOWS bassinet pad distribution40% success